Kalol, India

Gyanchander Eppa

This inventor holds 1 USPTO granted patent. Top assignee: Cadila Corporate Campus. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gyanchander Eppa. Retrieved from https://idiyas.com/inventor/gyanchander-eppa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gyanchander Eppa: Innovator in Pharmaceutical Chemistry

Introduction

Gyanchander Eppa is a notable inventor based in Kalol, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the synthesis of novel compounds. His work focuses on developing intermediates that are essential for the preparation of important medications.

Latest Patents

Gyanchander Eppa holds a patent for the "Synthesis of novel intermediate(s) for preparing rivastigmine." This invention relates to novel intermediates that are useful for the preparation of the Rivastigmine compound and its pharmaceutically acceptable salts. The patent also details the processes for preparing these novel intermediates and the subsequent preparation of Rivastigmine using them.

Career Highlights

Eppa is currently associated with Cadila Corporate Campus, where he applies his expertise in pharmaceutical development. His innovative approach has led to advancements in the synthesis of critical compounds used in various therapeutic applications.

Collaborations

He has collaborated with notable colleagues, including Jhillu Singh Yadav and Pranav Rameshbhai Vachharajani, contributing to a dynamic research environment that fosters innovation.

Conclusion

Gyanchander Eppa's work exemplifies the impact of innovative thinking in the pharmaceutical industry. His contributions to the synthesis of novel intermediates are paving the way for advancements in medication development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…